PortalPublikationenTROP2 expression as prognostic marker for gastric carcinoma.

TROP2 expression as prognostic marker for gastric carcinoma.

Standard

TROP2 expression as prognostic marker for gastric carcinoma. / Mühlmann, G; Spizzo, G; Gostner, J; Zitt, M; Maier, Hannes; Moser, P; Gastl, G; Müller, H M; Margreiter, R; Ofner, D; Fong, D.

in: J CLIN PATHOL, Jahrgang 62, Nr. 2, 2, 2009, S. 152-158.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Mühlmann, G, Spizzo, G, Gostner, J, Zitt, M, Maier, H, Moser, P, Gastl, G, Müller, HM, Margreiter, R, Ofner, D & Fong, D 2009, 'TROP2 expression as prognostic marker for gastric carcinoma.', J CLIN PATHOL, Jg. 62, Nr. 2, 2, S. 152-158. <http://www.ncbi.nlm.nih.gov/pubmed/18930986?dopt=Citation>

APA

Mühlmann, G., Spizzo, G., Gostner, J., Zitt, M., Maier, H., Moser, P., Gastl, G., Müller, H. M., Margreiter, R., Ofner, D., & Fong, D. (2009). TROP2 expression as prognostic marker for gastric carcinoma. J CLIN PATHOL, 62(2), 152-158. [2]. http://www.ncbi.nlm.nih.gov/pubmed/18930986?dopt=Citation

Vancouver

Mühlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P et al. TROP2 expression as prognostic marker for gastric carcinoma. J CLIN PATHOL. 2009;62(2):152-158. 2.

Bibtex

@article{262b5e711b144be8876733451cec1e81,
title = "TROP2 expression as prognostic marker for gastric carcinoma.",
abstract = "BACKGROUND: In gastric cancer the recurrence rate is unacceptably high, even after R0 resection and (neo)adjuvant chemotherapy. Therefore, there is an urgent need for identification of predictive and/or prognostic biomarkers to select high-risk patients who might benefit from additional therapies. Expression of TROP2 has been shown to be associated with tumour aggressiveness and poor prognosis in patients with various epithelial cancers. AIMS: To investigate TROP2 expression in gastric cancer and its correlation with clinicopathological features and disease outcome. METHODS: Expression of TROP2 was investigated by immunohistochemistry of tumour specimens from 104 patients who underwent resection for gastric cancer. Parameters found to be of prognostic significance in univariate analysis were verified in a multivariate Cox regression model. RESULTS: TROP2 was found to be overexpressed in 58 (56%) tumour samples. Significantly higher expression of TROP2 could be detected in intestinal-type carcinomas (p = 0.03). In intestinal-type gastric cancer, TROP2 overexpression was significantly correlated with shorter disease-free survival (DFS) (p = 0.03). Among the total group, TROP2 overexpression was predictive for poor disease-free (p",
author = "G M{\"u}hlmann and G Spizzo and J Gostner and M Zitt and Hannes Maier and P Moser and G Gastl and M{\"u}ller, {H M} and R Margreiter and D Ofner and D Fong",
year = "2009",
language = "Deutsch",
volume = "62",
pages = "152--158",
journal = "J CLIN PATHOL",
issn = "0021-9746",
publisher = "BMJ PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - TROP2 expression as prognostic marker for gastric carcinoma.

AU - Mühlmann, G

AU - Spizzo, G

AU - Gostner, J

AU - Zitt, M

AU - Maier, Hannes

AU - Moser, P

AU - Gastl, G

AU - Müller, H M

AU - Margreiter, R

AU - Ofner, D

AU - Fong, D

PY - 2009

Y1 - 2009

N2 - BACKGROUND: In gastric cancer the recurrence rate is unacceptably high, even after R0 resection and (neo)adjuvant chemotherapy. Therefore, there is an urgent need for identification of predictive and/or prognostic biomarkers to select high-risk patients who might benefit from additional therapies. Expression of TROP2 has been shown to be associated with tumour aggressiveness and poor prognosis in patients with various epithelial cancers. AIMS: To investigate TROP2 expression in gastric cancer and its correlation with clinicopathological features and disease outcome. METHODS: Expression of TROP2 was investigated by immunohistochemistry of tumour specimens from 104 patients who underwent resection for gastric cancer. Parameters found to be of prognostic significance in univariate analysis were verified in a multivariate Cox regression model. RESULTS: TROP2 was found to be overexpressed in 58 (56%) tumour samples. Significantly higher expression of TROP2 could be detected in intestinal-type carcinomas (p = 0.03). In intestinal-type gastric cancer, TROP2 overexpression was significantly correlated with shorter disease-free survival (DFS) (p = 0.03). Among the total group, TROP2 overexpression was predictive for poor disease-free (p

AB - BACKGROUND: In gastric cancer the recurrence rate is unacceptably high, even after R0 resection and (neo)adjuvant chemotherapy. Therefore, there is an urgent need for identification of predictive and/or prognostic biomarkers to select high-risk patients who might benefit from additional therapies. Expression of TROP2 has been shown to be associated with tumour aggressiveness and poor prognosis in patients with various epithelial cancers. AIMS: To investigate TROP2 expression in gastric cancer and its correlation with clinicopathological features and disease outcome. METHODS: Expression of TROP2 was investigated by immunohistochemistry of tumour specimens from 104 patients who underwent resection for gastric cancer. Parameters found to be of prognostic significance in univariate analysis were verified in a multivariate Cox regression model. RESULTS: TROP2 was found to be overexpressed in 58 (56%) tumour samples. Significantly higher expression of TROP2 could be detected in intestinal-type carcinomas (p = 0.03). In intestinal-type gastric cancer, TROP2 overexpression was significantly correlated with shorter disease-free survival (DFS) (p = 0.03). Among the total group, TROP2 overexpression was predictive for poor disease-free (p

M3 - SCORING: Zeitschriftenaufsatz

VL - 62

SP - 152

EP - 158

JO - J CLIN PATHOL

JF - J CLIN PATHOL

SN - 0021-9746

IS - 2

M1 - 2

ER -